Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis in Iran

Conclusion: Compared to no treatment, Teriparatide was indicated to be more costly and associated with fewer fractures, more life-years, and more QALYs. The result showed that Teriparatide may be considered a cost-effective intervention when targeted to the appropriate patients.
Source: Iranian Journal of Pharmaceutical Research - Category: Drugs & Pharmacology Source Type: research